ADP-A2M4CD8,Nivolumab
adaptimmune therapeutics,bms
['a2m4cd8', 'urothelial', 'esophageal', 'gastroesophageal', 'ovarian', 'head and neck', 'adp-a2m4', 'solid tumor']
adp-a2m4cd8, a cd8+ tcr t-cell therapy has yielded responses across a variety of mage-a4+ solid tumors, including ovarian, urothelial, gastroesophageal, and head and neck cancers. #esmo22 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.